ArticleBioscience reports2020
Comment on "Expression of CD44 and the survival in glioma: a meta-analysis".
Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Redox-Regulated Pathways in Glioblastoma Stem-like Cells: Mechanistic Insights and Therapeutic Implications.Brain sciences · 2025Review
- Impairing proliferation of glioblastoma multiforme with CD44+ selective conjugated polymer nanoparticles.Scientific reports · 2022Article
- Association of glioma CD44 expression with glial dynamics in the tumour microenvironment and patient prognosis.Computational and structural biotechnology journal · 2022Article
Corrections and comments
- Comment on
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD44 has been considered as a cancer stem cell marker in various tumors. With great enthusiasm, we read an article written by Wu et al. entitled "Expression of CD44 and the survival in glioma: a meta-analysis" published in Bioscience Reports. The authors performed meta-analyses to study the prognostic significance of CD44 in gliomas, and drew the conclusion that high expression of CD44 may predict poor survival in glioma, particularly in WHO grade II-III gliomas. However, two major defects exist in the present study, which made the meta-analysis on the prognostic significance of CD44 in all gliomas unreliable. In this commentary, we discussed the limitations and significance of the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.